Patents by Inventor Steven A. Ogata

Steven A. Ogata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • West nile virus vaccine comprising WN-80E recombinant subunit protein
    Patent number: 10039820
    Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 7, 2018
    Assignee: Hawaii Biotech, Inc.
    Inventors: Beth-Ann Coller, Vidya Pai, Carolyn L. Weeks-Levy, Steven A. Ogata
  • RECOMBINANT SUBUNIT WEST NILE VIRUS VACCINE FOR PROTECTION OF HUMAN SUBJECTS
    Publication number: 20170165349
    Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Application
    Filed: October 21, 2016
    Publication date: June 15, 2017
    Inventors: Beth-Ann Coller, Vidya Pai, Carolyn L. Weeks-Levy, Steven A. Ogata
  • RECOMBINANT SUBUNIT WEST NILE VIRUS VACCINE FOR PROTECTION OF HUMAN SUBJECTS
    Publication number: 20120141520
    Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Application
    Filed: June 1, 2010
    Publication date: June 7, 2012
    Inventors: Beth-Ann Coller, Vidya Pai, Carolyn Weeks-Levy, Steven A. Ogata